title: Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: a prospective analysis.
abstract: OBJECTIVE
  Most women with ovarian cancer relapse and undergo further chemotherapy however evidence regarding the benefits of this for women with platinum-resistant disease is limited. Our objective was to determine whether there was a quality of life improvement or treatment response among women treated for platinum-resistant recurrent ovarian cancer.
  
  
  METHODS
  We combined data from 2 studies where women treated with chemotherapy for recurrent ovarian cancer (n=172) completed a quality of life questionnaire every 3 months. Cancers were classified as platinum-resistant if they progressed within 6 months of completing first-line chemotherapy. Mixed effects models were used to analyze change in quality of life during the first 6 months after second-line chemotherapy.
  
  
  RESULTS
  One-quarter of women (n=44) were classified as having platinum-resistant disease. Overall, their quality of life did not significantly increase or decrease, following commencement of second-line chemotherapy (least square mean scores=107, 105, 103 at chemotherapy start, 3 and 6 months later, respectively), although 26% of these women reported a meaningful increase and 31% reported a meaningful decline. One-third of the platinum-resistant group responded (11% complete and 21% partial response) to second-line chemotherapy, and this figure increased to 54% among the subset (36%) re-treated with platinum-based agents with or without other agents. Preliminary analyses suggest that quality of life may be higher at chemotherapy initiation in women whose disease responded (median score 121 vs 110).
  
  
  CONCLUSIONS
  Overall, quality of life appears to be maintained in women with platinum-resistant ovarian cancer who receive further chemotherapy and some women respond to re-treatment.
authors.affiliation: Gynaecological Cancers Group, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia. Electronic address: Vanessa.Beesley@qimrberghofer.edu.au.
authors.forename: Vanessa L
authors.initials: VL
authors.lastname: Beesley
authors.affiliation: Cancer and Population Studies Group, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
authors.forename: Adele C
authors.initials: AC
authors.lastname: Green
authors.affiliation: Department of Medical Oncology, Royal Brisbane and Women's Hospital, Herston, QLD, Australia.
authors.forename: David K
authors.initials: DK
authors.lastname: Wyld
authors.affiliation: Statistics Unit, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
authors.forename: Peter
authors.initials: P
authors.lastname: O'Rourke
authors.affiliation: Statistics Unit, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
authors.forename: Leesa F
authors.initials: LF
authors.lastname: Wockner
authors.affiliation: Westmead Institute of Cancer Research, University of Sydney at Westmead Millennium Institute and Westmead Hospital, Sydney, NSW, Australia.
authors.forename: Anna
authors.initials: A
authors.lastname: deFazio
authors.affiliation: Centre for Medical Psychology and Evidence-Based Decision-Making, School of Psychology, The University of Sydney, Sydney, NSW, Australia.
authors.forename: Phyllis N
authors.initials: PN
authors.lastname: Butow
authors.affiliation: Centre for Medical Psychology and Evidence-Based Decision-Making, School of Psychology, The University of Sydney, Sydney, NSW, Australia.
authors.forename: Melanie A
authors.initials: MA
authors.lastname: Price
authors.affiliation: Greenslopes Specialist Centre, Greenslopes Private Hospital, Greenslopes, QLD, Australia.
authors.forename: Keith R
authors.initials: KR
authors.lastname: Horwood
authors.affiliation: School of Pharmacy, University of Queensland, St. Lucia, QLD, Australia.
authors.forename: Alexandra M
authors.initials: AM
authors.lastname: Clavarino
authors.affiliation: Gynaecological Cancers Group, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
authors.lastname: Australian Ovarian Cancer Study Group
authors.affiliation: Greenslopes Specialist Centre, Greenslopes Private Hospital, Greenslopes, QLD, Australia.
authors.lastname: Australian Ovarian Cancer Study-Quality Of Life Study Investigators
authors.affiliation: Gynaecological Cancers Group, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
authors.forename: Penelope M
authors.initials: PM
authors.lastname: Webb
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D010984:Platinum / Q000627:therapeutic use*; D011446:Prospective Studies; D011788:Quality of Life
chemical_list: D000970:Antineoplastic Agents; D010984:Platinum
keywords: Chemotherapy; Ovarian cancer; Platinum-resistance; Progression; Quality of life; Recurrence